MYC and colonic neoplasm: Clinical data from the past 5 years implicate the value of combining two or more targeted therapies to treat solid cancers as exemplified for colon cancer.98 Therefore, SUMO inhibitor combination therapies could be developed in order to treat MYC-hyperactivated PDACs.